Pharmacokinetics of tolfenamic acid in red-eared slider turtles (Trachemys scripta elegans)

Çorum, Orhan; Atik, Orkun; Çorum, Duygu Durna; Er, Ayşe; Üney, Kamil

doi:10.1016/j.vaa.2019.05.009

Cited by 16 publications

(50 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the 4 mg/kg TA compared with 2 mg/kg TA resulted in prolonged t 1/2ʎz (from 1.57 to 2.13 hr), increased dose‐normalized AUC 0‐∞ (from 6.64 to 21.21 hr*µg/ml), and decreased Cl T (from 0.30 to 0.19 L h ‐1 kg ‐1 ). Similar dose‐related changes have been reported in sheep and turtles (Corum et al., 2018, 2019). TA is metabolized by hydroxylation and then converted to conjugation metabolites and is excreted through urine and bile.…”

Section: Discussionsupporting

confidence: 83%

“…The plasma TA concentration was determined using the high‐performance liquid chromatography (HPLC) with ultraviolet detector by the previously method (Corum et al., 2018, 2019). Briefly, the 300 μl of acetonitrile was added to a 200 μl of goat plasma sample followed by vortexed for 30 s and centrifugation at 10,000 g for 15 min.…”

Section: Methodsmentioning

confidence: 99%

“…The pharmacokinetics of TA has been demonstrated in many animal species such as horses (Jaussaud et al., 1992), sheep (Corum, Corum, Er, Yildiz, & Uney, 2018), calves (Landoni, Cunningham, & Lees, 1996), dogs (Lefebvre et al., 1997), and turtles (Corum, Atik, Corum, Er, & Uney, 2019). The pharmacokinetics of TA after intramuscular administration was also established in goats (Sidhu et al., 2006).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of dose on the intravenous pharmacokinetics of tolfenamic acid in goats

Tekeli

Türk

Çorum

et al. 2020

Vet Pharm & Therapeutics

Self Cite

View full text Add to dashboard Cite

The objective of this study was to determine the pharmacokinetics of tolfenamic acid (TA) following intravenous (IV) administration at doses of 2 and 4 mg/kg in goats. In this study, six healthy goats were used. TA was administered intravenously to each goat at 2 and 4 mg/kg doses in a cross‐over pharmacokinetic design with a 15‐day washout period. Plasma concentrations of TA were analyzed using the high performance liquid chromatography with ultraviolet detector, and pharmacokinetic parameters were assigned by noncompartmental analysis. Following IV administration at dose of 2 mg/kg, area under the concentration–time curve (AUC0−∞), elimination half‐life (t1/2ʎz), total clearance (ClT) and volume of distribution at steady state (Vdss) were 6.64 ± 0.81 hr*µg/ml, 1.57 ± 0.14 hr, 0.30 ± 0.04 L h‐1 kg‐1 and 0.40 ± 0.05 L/kg, respectively. After the administration of TA at a dose of 4 mg/kg showed prolonged t1/2ʎz, increased dose‐normalized AUC0‐∞, and decreased ClT. In goats, TA at 4 mg/kg dose can be administered wider dose intervals compared to the 2 mg/kg dose. However, further studies are needed to determine the effect of different doses on the clinical efficacy of TA in goats.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of dose on the intravenous pharmacokinetics of tolfenamic acid in goats

Tekeli

Türk

Çorum

et al. 2020

Vet Pharm & Therapeutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…In our best knowledge, there are a few reports of TA in reptiles, including red‐eared slider turtles (Corum, Atik, Corum, Er, & Uney, 2019) and Hawksbill turtles (Raweewan et al, 2020). However, drug dosages in sea turtles are often extrapolated from domestic animals or members of similar taxonomic orders, but even careful allometric scaling based on similar species can result in unpredictable pharmacokinetic profiles and drug toxicoses.…”

Section: Discussionmentioning

confidence: 99%

“…The information concerning this class of drugs in reptiles and especially in marine turtles is scarce, and drug doses are often extrapolated from those reported for other animal species. There are a few reports in reptiles, including TA in red‐eared slider turtles (Corum et al, 2019) and Hawksbill turtles (Raweewan et al, 2020). Therefore, the aim of this study was to evaluate the pharmacokinetic characteristics of TA in green sea turtles ( Chelonia mydas ) after single i.v.…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics of tolfenamic acid in green sea turtles (Chelonia mydas) after intravenous and intramuscular administration

Raweewan

Chomcheun²,

Laovechprasit³

et al. 2020

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

The present study aimed to evaluate the pharmacokinetic features of tolfenamic acid (TA) in green sea turtles, Chelonia mydas. Green sea turtles were administered single either intravenous (i.v.) or intramuscular (i.m.) injection of TA, at a dose of 4 mg/kg body weight (b.w.). Blood samples were collected at preassigned times up to 168 hr. The plasma concentrations of TA were measured using a validated liquid chromatography tandem mass spectrometry method. Tolfenamic acid plasma concentrations were quantifiable for up to 168 hr after i.v. and i.m. administration. The concentration of TA in the experimental green sea turtles with respect to time was pharmacokinetically analyzed using a noncompartment model. The Cmax values of TA were 55.01 ± 8.34 µg/ml following i.m. administration. The elimination half‐life values were 32.76 ± 4.68 hr and 53.69 ± 3.38 hr after i.v. and i.m. administration, respectively. The absolute i.m. bioavailability was 72.02 ± 10.23%, and the average binding percentage of TA to plasma protein was 19.43 ± 6.75%. Based on the pharmacokinetic data, the i.m. administration of TA at a dosage of 4 mg/kg b.w. might be sufficient to produce a long‐lasting anti‐inflammatory effect (7 days) for green sea turtles. However, further studies are needed to determine the clinical efficacy of TA for treatment of inflammatory disease after single and multiple dosages.

show abstract

Pharmacokinetics, bioavailability and plasma protein binding of tolfenamic acid in rainbow trout (Oncorhynchus mykiss)

Corum,

Durna Corum,

Marin

et al. 2024

Veterinary Medicine & Sci

Self Cite

View full text Add to dashboard Cite

BackgroundAlthough research on the mechanism and control of pain and inflammation in fish has increased in recent years, the use of analgesic drugs is limited due to the lack of pharmacological information about analgesic drugs. Tolfenamic acid is a non‐steroidal anti‐inflammatory drug and can be used in fish due to its low side effect profile and superior pharmacokinetic properties.ObjectivesThe pharmacokinetics, bioavailability and plasma protein binding of tolfenamic acid were investigated following single intravascular (IV), intramuscular (IM) and oral administration of 2 mg/kg in rainbow trout at 13 ± 0.5°C.MethodsThe experiment was carried out on a total of 234 rainbow trout (Oncorhynchus mykiss). Tolfenamic acid was administered to fish via IV, IM and oral route at a dose of 2 mg/kg. Blood samples were taken at 13 different sampling times until the 72 h after drug administration. The plasma concentrations of tolfenamic acid were quantified using high pressure liquid chromatography–ultraviolet (UV) and pharmacokinetic parameters were assessed using non‐compartmental analysis.ResultsThe elimination half‐life (t1/2ʎz) of tolfenamic acid for IV, IM and oral routes was 3.47, 6.75 and 9.19 h, respectively. For the IV route, the volume of distribution at a steady state and total body clearance of tolfenamic acid were 0.09 L/kg and 0.03 L/h/kg, respectively. The peak plasma concentration and bioavailability for IM and oral administration were 8.82 and 1.24 µg/mL, and 78.45% and 21.48%, respectively. The mean plasma protein binding ratio of tolfenamic acid in rainbow trout was 99.48% and was not concentration dependent.ConclusionsWhile IM route, which exhibits both the high plasma concentration and bioavailability, can be used in rainbow trout, oral route is not recommended due to low plasma concentration and bioavailability. However, there is a need to demonstrate the pharmacodynamic activity of tolfenamic acid in rainbow trout.

show abstract

Pharmacokinetics of tolfenamic acid in red-eared slider turtles (Trachemys scripta elegans)

Cited by 16 publications

References 30 publications

Effect of dose on the intravenous pharmacokinetics of tolfenamic acid in goats

Effect of dose on the intravenous pharmacokinetics of tolfenamic acid in goats

Pharmacokinetics of tolfenamic acid in green sea turtles (Chelonia mydas) after intravenous and intramuscular administration

Pharmacokinetics, bioavailability and plasma protein binding of tolfenamic acid in rainbow trout (Oncorhynchus mykiss)

Contact Info

Product

Resources

About